Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.39 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31562691 | 0.87 | ERN1 (0.65) | ERN1LMNACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL31562831 | 0.80 | HDAC8 (0.47) | ERN1LMNACYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL31562452 | 0.80 | HDAC8 (0.47) | ERN1LMNACYP3A4SMN1; SMN2KDM4E | |
| SCHEMBL829755 | 0.78 | ERN1 (1.00) | ERN1LMNACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL30294862 | 0.77 | ERN1 (0.96) | ERN1LMNACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL7031594 | 0.75 | ERN1 (0.78) | ERN1LMNACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL23442397 | 0.72 | ERN1 (0.73) | ERN1LMNACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL31562188 | 0.71 | ERN1 (0.67) | ERN1LMNACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL5623138 | 0.71 | ERN1 (0.71) | ERN1LMNACYP3A4SMN1; SMN2USP2 | |
| SCHEMBL4833961 | 0.70 | ERN1 (0.60) | ERN1LMNACYP3A4MAPK1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| WO-2025090658-A2 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289789-A1 | REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF | CDK2, CDK20, CDK1 | ERN1 1389/4885LMNA 1059/4885CYP3A4 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.